Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01672229 · ClinicalTrials.gov registry record · Phase 1
Bortezomib in Patients With Chronic Graft Versus Host Disease
A Phase 1 study, sponsored by Mehrdad Abedi, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01672229: Completed Phase 1 study, sponsored by Mehrdad Abedi, MD.
NCT01672229 is a Phase 1 study that has completed, run by Mehrdad Abedi, MD. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01672229, a Phase 1 study, has completed, sponsored by Mehrdad Abedi, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study will investigate whether bortezomib can control the immune system and can be used to treat GVHD. Bortezomib has been used with not too many serious side effects in patients with multiple myeloma who will undergo transplant and also for acute graft versus host disease.
Primary Outcome
Safety assessments will consist of monitoring and recording all adverse events and serious adverse events, the regular monitoring of hematology, blood chemistry, regular measurement of vital signs and the performance of physical examination. Safety will be assessed according to the NCI CTCAE v4.
Interventions
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-07 |
| Est. Completion | 2018-04-09 |
| Phase | Phase 1 |
What the finished NCT01672229 record still lists
NCT01672229 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 1 intervention - of which Bortezomib is the first listed.
NCT01672229 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01672229 about?
NCT01672229 is a clinical study titled "Bortezomib in Patients With Chronic Graft Versus Host Disease". This study will investigate whether bortezomib can control the immune system and can be used to treat GVHD. Bortezomib has been used with not too many serious side effects in patients with multiple myeloma who will undergo transplant and also for acute graft versus host disease.
What is the current status of trial NCT01672229?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2012-07. Estimated completion is 2018-04-09.
What interventions are being tested in trial NCT01672229?
The interventions under investigation include: Bortezomib (DRUG).
Who is sponsoring clinical trial NCT01672229?
This trial is sponsored by Mehrdad Abedi, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01672229's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia